NVCT

Nuvectis Pharma Inc

20.13

Oct 08 • 3:59 PM ET -0.16 (-0.79%)

20.13

Aftermarket • 5:00 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: ALXO FHTX IKT BCYC CGEN FATE NBP NERV CDXS AKTX

| Held by: VTI IWM VXF IWO VTWO FESM DWAS IWC ITOT GSSC

Index	RUT
Market Cap	657.13M
Enterprise Value	634.97M
Income	-30.27M
Sales	0.00M
Book/sh	0.34
Cash/sh	0.68
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	13
IPO	Feb 04, 2022

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	59.17
P/C	29.65
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.68
Current Ratio	1.68
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-1.28
EPS next Y	-1.15
EPS next Q	-0.24
EPS this Y	20.96%
EPS next Y	-10.38%
EPS next 5Y	2.54%
EPS past 3/5Y	4.25% -340.28%
Sales past 3/5Y	- -
EPS Y/Y TTM	-13.52%
Sales Y/Y TTM	-
EPS Q/Q	-0.88%
Sales Q/Q	-
Earnings	Aug 04 BMO
EPS/Sales Surpr.	-14.50% -

Insider Own	35.16%
Insider Trans	0.55%
Inst Own	33.18%
Inst Trans	55.33%
ROA	-122.61%
ROE	-233.30%
ROIC	-333.35%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-6.23%
SMA50	-7.67%
SMA200	46.68%
Trades

Shs Outstand	26.69M
Shs Float	21.17M
Short Float	11.16%
Short Ratio	10.79
Short Interest	2.36M
52W High	29.27 -31.24%
52W Low	5.55 262.70%
Volatility	7.00% 7.19%
ATR (14)	1.47
RSI (14)	42.92
Beta	-0.25
Rel Volume	0.82
Avg Volume	218.95K
Volume	179,390

Perf Week	-2.85%
Perf Month	-11.63%
Perf Quarter	9.70%
Perf Half Y	146.69%
Perf YTD	166.62%
Perf Year	223.11%
Perf 3Y	78.14%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	35.40
Prev Close	20.29
Price	20.13
Change %	-0.79%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-24-26	Initiated	Cantor Fitzgerald	Overweight
Apr-02-25	Initiated	Maxim Group	Buy	$17
Mar-17-25	Initiated	Laidlaw	Buy	$19
Jul-13-22	Initiated	Ladenburg Thalmann	Buy	$21

Sep-25-26 08:00AM	Nuvectis' In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It's Not Even Their Lead Asset (FinanceWire) -6.52%
Sep-24-26 08:00AM	Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma (GlobeNewswire)
Sep-03-26 08:00AM	Some of the Top Biotech Funds Just Bought Into This Under-the-Radar Biotech (NASDAQ: NVCT) (FinanceWire)
08:00AM	Nuvectis Pharma To Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-04-26 08:00AM	Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights (GlobeNewswire) -6.94%
11:56AM	Loading…
Jul-23-26 11:56AM	Nuvectis' NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor (FinanceWire)
09:00AM	Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors (GlobeNewswire)
07:30AM	Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors (GlobeNewswire)
Jul-14-26 10:40AM	StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data (Newsfile)
Jul-09-26 07:35AM	The Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush (FinanceWire)
Jun-30-26 08:36AM	Nuvectis Pharma shares slide after pricing $100 million discounted stock offering (NVCT) (InvestorsHub) -35.54%
Jun-29-26 10:30PM	Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock (GlobeNewswire)
04:01PM	Nuvectis Pharma Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jun-24-26 05:10AM	Haisco and Nuvectis sign licensing deal for two drugs (Pharmaceutical Technology) +39.49%
Jun-22-26 08:53AM	Nuvectis Expands Pipeline with Haisco Licensing Agreement for Two Clinical-Stage Drug Candidates (NVCT) (InvestorsHub) +19.61%
07:30AM	Loading…
07:30AM	Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds (GlobeNewswire)
May-14-26 07:30AM	Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-05-26 07:30AM	Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights (GlobeNewswire) +9.22%
Mar-31-26 08:00AM	Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting (GlobeNewswire)
Feb-11-26 07:30AM	Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights (GlobeNewswire)
Dec-17-25 07:00AM	Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC (GlobeNewswire)
Nov-25-25 08:00AM	Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC (GlobeNewswire)
Nov-04-25 08:15AM	CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights (GlobeNewswire) -7.55%
07:30AM	Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
Oct-27-25 08:00AM	Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire) +5.65%
Oct-16-25 08:00AM	Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-25-25 08:00AM	Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors (GlobeNewswire)
Sep-04-25 07:30AM	Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-11-25 04:30PM	Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900 (GlobeNewswire) +11.26%
Aug-05-25 07:30AM	Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights (GlobeNewswire) -5.35%
07:41AM	Loading…
Aug-04-25 07:41AM	Nuvectis Pharma cuts NXP800 in ovarian cancer after early failure (Clinical Trials Arena) +7.21%
Jul-31-25 07:45AM	Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study (GlobeNewswire) -7.81%
Jul-08-25 08:00AM	Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies (GlobeNewswire)
May-16-25 04:35PM	Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference (GlobeNewswire) +6.36% +10.94%
May-09-25 09:55AM	Does Nuvectis Pharma (NVCT) Have the Potential to Rally 108.79% as Wall Street Analysts Expect? (Zacks)
May-06-25 08:00AM	Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
Apr-30-25 05:28AM	Why Nuvectis Pharma, Inc. (NVCT) is Surging in 2025 (Insider Monkey)
Apr-29-25 04:25PM	Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting (GlobeNewswire)
Mar-26-25 08:00AM	Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting (GlobeNewswire)
Mar-14-25 08:00AM	Nuvectis Pharma to Participate in the 37th Annual Roth Conference (GlobeNewswire) +5.99%
Mar-05-25 08:44AM	Market News Alert: Nuvectis Pharmas NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation (Business Wire)
Mar-04-25 08:00AM	Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC (GlobeNewswire)
Feb-27-25 10:43AM	Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets (Business Wire)
Feb-25-25 08:00AM	Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights (GlobeNewswire) -5.84%
Feb-07-25 08:30AM	Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter's Over-Allotment Option (GlobeNewswire) -7.32%
Feb-05-25 09:01AM	Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock (GlobeNewswire)
Feb-04-25 04:05PM	Nuvectis Pharma Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Dec-10-24 08:00AM	Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators and Investors Symposium (GlobeNewswire)
08:00AM	Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium (GlobeNewswire)
Nov-25-24 09:55AM	Nuvectis Pharma (NVCT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Nov-15-24 07:45AM	Nuvectis Pharma reports data from Phase 1b study of NXP800 (TipRanks) -13.61%
Nov-14-24 02:23PM	Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug (Benzinga) -46.30%
07:00AM	Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer (GlobeNewswire)
Nov-13-24 08:50AM	Nuvectis Pharma (NVCT) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Nov-07-24 09:55AM	Wall Street Analysts Predict a 169.94% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know (Zacks)
Nov-05-24 07:00AM	Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) +17.75%
Oct-28-24 08:21AM	PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update (Business Wire) -10.50%
Oct-23-24 08:00AM	Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire) +5.33%
Oct-07-24 08:00AM	Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference (GlobeNewswire)
Sep-16-24 07:15AM	PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch (Business Wire)
Sep-05-24 08:00AM	Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -6.81%
Aug-30-24 06:52AM	Nuvectis NXP800 gains FDA ODD for cancer treatment (Pharmaceutical Technology)
Aug-29-24 08:00AM	Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers (GlobeNewswire)
Aug-06-24 08:28AM	Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) -5.83%
May-28-24 06:10AM	7 Penny Biotech Stocks to Triple Your Investment (InvestorPlace) +5.96%
May-24-24 09:55AM	Wall Street Analysts See a 229.34% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High? (Zacks) -7.04%
May-16-24 08:30AM	Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference (GlobeNewswire)
May-07-24 09:06PM	Nuvectis Pharma Inc Reports Q1 2024 Financial Outcomes (GuruFocus.com) -10.57%
01:53PM	NVCT Stock Earnings: Nuvectis Pharma Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Apr-08-24 08:30AM	Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines (GlobeNewswire)
Apr-02-24 04:30PM	5 Healthcare Stocks to Buy for 2024 (InvestorPlace)
Mar-19-24 08:00AM	Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting (GlobeNewswire) -16.08%
Mar-15-24 08:00AM	Nuvectis Pharma to Present at the 36th Annual Roth Conference (GlobeNewswire) +20.22%
Mar-14-24 09:00AM	Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer (GlobeNewswire) -5.08%
Mar-05-24 11:52PM	NVCT Stock Earnings: Nuvectis Pharma Misses EPS for Q4 2023 (InvestorPlace)
08:31AM	Nuvectis Pharma Inc (NVCT) Reports Increased Net Loss in FY 2023 Despite Clinical Progress (GuruFocus.com)
08:00AM	Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights (GlobeNewswire)
Feb-09-24 08:32AM	Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
08:00AM	Nuvectis Pharma Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Jan-03-24 08:00AM	Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-23 08:00AM	Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma (GlobeNewswire)
Nov-08-23 08:00AM	Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) -7.83%
Oct-24-23 08:00AM	Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer (GlobeNewswire)
Oct-16-23 09:35AM	Down -36.49% in 4 Weeks, Here's Why You Should You Buy the Dip in Nuvectis Pharma, Inc. (NVCT) (Zacks) +15.87%
Sep-25-23 07:30PM	Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation (GlobeNewswire)
Sep-21-23 08:00AM	Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900 (GlobeNewswire)
Sep-12-23 08:00AM	Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial (GlobeNewswire)
Sep-06-23 08:00AM	Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900 (GlobeNewswire)
Sep-01-23 08:00AM	Nuvectis Pharma Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Aug-17-23 08:00AM	Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma (GlobeNewswire)
Aug-11-23 07:01AM	Daily Vickers Top Insider Picks for 08/11/2023 (Argus Research)
Aug-10-23 06:24AM	Daily Vickers Top Insider Picks for 08/10/2023 (Argus Research)
Aug-09-23 08:00AM	Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
06:26AM	Daily Vickers Top Insider Picks for 08/09/2023 (Argus Research)
Aug-08-23 06:28AM	Daily Vickers Top Insider Picks for 08/08/2023 (Argus Research)
Aug-07-23 06:35AM	Daily Vickers Top Insider Picks for 08/07/2023 (Argus Research)
Aug-04-23 07:14AM	Daily Vickers Top Insider Picks for 08/04/2023 (Argus Research)
Aug-03-23 07:15AM	Daily Vickers Top Insider Picks for 08/03/2023 (Argus Research)
Aug-02-23 07:52AM	Daily Vickers Top Insider Picks for 08/02/2023 (Argus Research) +7.41%

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its product pipeline includes NXP800 and NXP900. The company was founded by Ronald E. Bentsur, Enrique Poradosu, and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.

Co-FounderMr. Ron Bentsur M.B.A.

Co-FounderDr. Enrique Poradosu Ph.D.

Co-FounderMr. Shay Shemesh

Vice President of FinanceMr. Michael Carson CPA

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mosseri Marlio Charles	10% Owner	Jun 30 '26	Buy	18.32	50,000	916,000	3,186,576	Jul 01 01:41 PM
BENTSUR RON	Chairman & CEO	Jun 30 '26	Buy	20.00	12,500	250,000	3,688,424	Jul 01 01:39 PM
BENTSUR RON	Chairman & CEO	Nov 05 '25	Buy	5.72	5,000	28,600	3,525,924	Nov 06 08:01 AM
Sanchez Juan	Director	Nov 05 '25	Buy	5.79	13,000	75,270	78,150	Nov 06 08:00 AM
Kaplan Matthew L.	Director	Nov 05 '25	Buy	5.84	11,000	64,240	124,760	Nov 06 08:00 AM
Mosseri Marlio Charles	10% Owner	Oct 27 '25	Buy	6.28	72,836	457,410	3,136,576	Oct 29 08:00 AM
Mosseri Marlio Charles	10% Owner	Oct 23 '25	Buy	6.06	46,900	284,214	3,028,706	Oct 29 08:00 AM
Mosseri Marlio Charles	10% Owner	Oct 24 '25	Buy	6.15	35,034	215,459	3,063,740	Oct 29 08:00 AM

Open in Screener

XAIR

Beyond Air Inc

2.31

Oct 08 • 3:59 PM ET -0.23 (-9.06%)

2.36

Aftermarket • 5:00 PM ET +0.05 (2.16%)

Healthcare Medical Devices USA Nano NASD

Peers: BMRA FEED HSCS INBS IVF NXL TNON AEMD NUWE VJET

| Held by: VXF

Index	-
Market Cap	2.27M
Enterprise Value	11.49M
Income	-33.49M
Sales	7.69M
Book/sh	2.69
Cash/sh	15.46
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	54
IPO	Sep 23, 2016

P/E	-
Forward P/E	-
PEG	-
P/S	0.30
P/B	0.86
P/C	0.15
P/FCF	-
EV/EBITDA	-
EV/Sales	1.49
Quick Ratio	3.12
Current Ratio	3.31
Debt/Eq	11.80
LT Debt/Eq	11.57
Option/Short	No / Yes

EPS (ttm)	-68.49
EPS next Y	-
EPS next Q	-3.31
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	52.44% 30.89%
Sales past 3/5Y	- 54.47%
EPS Y/Y TTM	71.34%
Sales Y/Y TTM	60.75%
EPS Q/Q	64.13%
Sales Q/Q	0.45%
Earnings	Aug 13 BMO
EPS/Sales Surpr.	-1.85% -8.35%

Insider Own	14.77%
Insider Trans	69.19%
Inst Own	6.99%
Inst Trans	-0.87%
ROA	-109.80%
ROE	-561.77%
ROIC	-133.22%
Gross Margin	4.18%
Oper. Margin	-364.76%
Profit Margin	-435.71%
SMA20	-20.69%
SMA50	-44.55%
SMA200	-80.49%
Trades

Shs Outstand	0.98M
Shs Float	0.84M
Short Float	7.06%
Short Ratio	0.27
Short Interest	0.06M
52W High	55.60 -95.85%
52W Low	2.38 -2.94%
Volatility	7.68% 7.47%
ATR (14)	0.32
RSI (14)	28.74
Beta	0.21
Rel Volume	0.46
Avg Volume	217.83K
Volume	99,799

Perf Week	-21.16%
Perf Month	-27.36%
Perf Quarter	-72.30%
Perf Half Y	-85.70%
Perf YTD	-84.09%
Perf Year	-95.64%
Perf 3Y	-99.76%
Perf 5Y	-99.95%
Perf 10Y	-99.98%
Recom	1.00
Target Price	18.33
Prev Close	2.54
Price	2.31
Change %	-9.06%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-01-26	Initiated	Lake Street	Buy	$10
Jul-17-25	Initiated	D. Boral Capital	Buy	$11
Jun-25-24	Downgrade	BTIG Research	Buy → Neutral
Jul-28-23	Initiated	Piper Sandler	Overweight	$10
Jun-15-23	Initiated	BTIG Research	Buy	$15
Apr-28-21	Initiated	Truist	Buy	$12
Oct-22-19	Initiated	Oppenheimer	Outperform	$9

Today 08:00AM	Beyond Air Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026 (GlobeNewswire) -9.06%
Sep-02-26 08:00AM	Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-31-26 08:00AM	Beyond Air Receives FDA Breakthrough Device Designation for LungFit GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) (GlobeNewswire) -11.38%
Aug-25-26 07:00AM	Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments (GlobeNewswire)
Aug-13-26 07:09PM	Beyond Air Inc (XAIR) (Q1 2027) Earnings Call Highlights: Strategic Financing and Pipeline ... (GuruFocus.com) +14.38% -8.74%
05:08PM	Loading…
05:08PM	Beyond Air, Inc. Q1 2027 Earnings Call Summary (Moby)
07:00AM	Beyond Air Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update (GlobeNewswire)
Aug-04-26 08:00AM	Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026 (GlobeNewswire)
Jul-30-26 07:00AM	Beyond Air Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Jun-27-26 08:30AM	Beyond Air, Inc. Q4 2026 Earnings Call Summary (Moby)
Jun-26-26 03:00PM	Beyond Air Inc (XAIR) Q4 2026 Earnings Call Highlights: Revenue Surge and Path to Profitability (GuruFocus.com)
07:00AM	Beyond Air Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-22-26 04:01PM	Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast (GlobeNewswire) +13.61% +14.43%
Jun-10-26 08:00AM	Beyond Air, Inc. Urges Stockholders to Vote "FOR" All Proposals Ahead of the Upcoming Special Meeting (GlobeNewswire)
Jun-01-26 08:00AM	Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing (GlobeNewswire) +5.70%
08:00AM	Loading…
Apr-20-26 08:00AM	Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026 (GlobeNewswire)
Apr-15-26 08:00AM	Beyond Air to Participate in the D. Boral Capital Global Conference 2026 (GlobeNewswire) -11.58%
Apr-01-26 09:00AM	Beyond Air Expands Commercial Access for LungFit PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO) (GlobeNewswire)
Mar-26-26 04:05PM	Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO (GlobeNewswire) -6.74%
Mar-17-26 04:35PM	Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial (GlobeNewswire)
Mar-11-26 07:00AM	Beyond Air to Participate in the 38th Annual Roth Conference in March (GlobeNewswire)
Mar-10-26 07:30AM	Beyond Air Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd. (GlobeNewswire)
Mar-04-26 05:39AM	Beyond Air Inc (XAIR) Expands Focus on Nitric Oxide Therapies (Insider Monkey)
Feb-20-26 08:00PM	Beyond Air Inc (XAIR) Q3 2026 Earnings Call Highlights: Impressive Revenue Growth and Strategic ... (GuruFocus.com) -7.34%
08:00AM	Beyond Air Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections (GlobeNewswire)
Feb-13-26 04:32PM	Beyond Air, Inc. Q3 2026 Earnings Call Summary (Moby)
07:30AM	Beyond Air Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-04-26 08:00AM	Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026 (GlobeNewswire) -5.22%
Jan-27-26 04:05PM	Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences (GlobeNewswire) -7.53% -5.93%
Jan-26-26 04:05PM	Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast (GlobeNewswire) -9.88%
08:30AM	Loading…
Jan-14-26 08:30AM	Beyond Air Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -14.16%
Jan-13-26 01:40PM	Beyond Air Deals Autism-Focused NeuroNOS To XTL For Equity, Future Payments (Benzinga) +150.00%
07:30AM	XTL Biopharmaceuticals Acquires 85% of Beyond Air's Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership (GlobeNewswire)
Dec-30-25 07:30AM	Beyond Air Appoints Dan Moorhead as Chief Financial Officer (GlobeNewswire)
Dec-17-25 07:30AM	Beyond Air Signs New International LungFit PH Distribution Agreements, Most Notably in Germany and Brazil (GlobeNewswire)
Nov-26-25 04:30PM	Beyond Air Announces Transition of Chief Financial Officer (GlobeNewswire)
Nov-11-25 12:02AM	Beyond Air Inc (XAIR) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amid Operational ... (GuruFocus.com) -16.09%
Nov-10-25 04:05PM	Beyond Air Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-05-25 08:00AM	Beyond Air Secures Up to $32 Million to Accelerate Growth (GlobeNewswire)
Oct-23-25 08:00AM	Beyond Air Schedules Second Fiscal Quarter 2026 Financial Results Conference Call and Webcast (GlobeNewswire)
Sep-22-25 08:00AM	Beyond Air to Participate in the ROTH 4th Annual Healthcare Opportunities Conference (GlobeNewswire) +5.38%
Sep-08-25 03:55PM	Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds (GlobeNewswire) +49.77%
08:00AM	NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults (GlobeNewswire)
Sep-03-25 08:00AM	Beyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-20-25 08:00AM	Beyond Air Signs New International LungFit PH Distribution Agreements, Most Notably in Japan (GlobeNewswire) -6.55%
Aug-13-25 03:11AM	Beyond Air Inc (XAIR) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Expansion ... (GuruFocus.com) -22.47%
Aug-12-25 05:35PM	Beyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Beyond Air Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-11-25 09:45AM	Beyond Air Inc (XAIR) Q1 2026 Earnings Report Preview: What To Expect (GuruFocus.com) +5.33%
Aug-07-25 06:20PM	AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +5.63%
Jul-25-25 08:00AM	Beyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and Webcast (GlobeNewswire)
Jul-22-25 07:30AM	Beyond Air Awarded Therapeutic Gases Agreement with Premier, Inc. (GlobeNewswire)
Jun-26-25 09:55AM	Here's Why Beyond Air (XAIR) Could be Great Choice for a Bottom Fisher (Zacks) -6.47%
Jun-18-25 03:01AM	Beyond Air Inc (XAIR) (Q4 2025) Earnings Call Highlights: Revenue Soars Amidst Strategic Global ... (GuruFocus.com) -29.02%
Jun-17-25 05:15PM	Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +58.69%
04:01PM	Beyond Air Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-16-25 09:16AM	Beyond Air Inc (XAIR) Q4 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
08:00AM	Beyond Air Submits FDA PMA Supplement for Next Generation LungFit PH (GlobeNewswire)
May-29-25 08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
May-28-25 05:20PM	Veeva Systems (VEEV) Q1 Earnings and Revenues Beat Estimates (Zacks)
May-20-25 08:00AM	Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast (GlobeNewswire)
Apr-24-25 04:05PM	Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO) (GlobeNewswire)
Apr-21-25 04:05PM	NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism (GlobeNewswire)
Apr-15-25 04:05PM	NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board (GlobeNewswire)
Apr-09-25 04:05PM	Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit GO at Home (GlobeNewswire) +11.63%
Apr-01-25 08:00AM	NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer's Disease and Reinforcing Platform's Strength Across Neurological Disorders (GlobeNewswire) -8.22%
Mar-31-25 08:00AM	Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site (GlobeNewswire)
Mar-24-25 04:05PM	NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy (GlobeNewswire) +5.63%
Mar-23-25 08:38AM	Beyond Air (XAIR): Among the Penny Stocks With Huge Upside Potential According to Analysts (InsiderMonkey)
Mar-11-25 07:30AM	Beyond Air Announces Agreements Expanding Global Distribution of LungFit PH (GlobeNewswire)
Mar-06-25 04:05PM	Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences (GlobeNewswire) -6.06%
Feb-10-25 04:05PM	Beyond Air Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +5.37% -6.49%
Feb-07-25 07:10AM	Beyond Air Inc (XAIR) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Feb-05-25 09:29AM	Beyond Air Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement (GlobeNewswire)
Jan-27-25 04:05PM	Beyond Air Schedules Third Fiscal Quarter 2025 Financial Results Conference Call and Webcast (GlobeNewswire) -7.83%
Jan-24-25 09:15AM	Beyond Air Announces LungFit PH Receives Market Authorization in Australia (GlobeNewswire)
Jan-06-25 08:00AM	Beyond Air to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 (GlobeNewswire)
Dec-03-24 04:05PM	Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy (GlobeNewswire) +7.85% -8.67%
Dec-02-24 07:30AM	Beyond Air Receives CE Mark in Europe for the LungFit PH System (GlobeNewswire)
Nov-26-24 07:30AM	NeuroNOS Appoints Nobel Laureate, Roger D. Kornberg, to Scientific Advisory Board (GlobeNewswire) +22.16%
Nov-14-24 04:05PM	Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire) +9.71% -5.38%
Nov-11-24 04:05PM	Beyond Air Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +7.64%
07:00AM	Beyond Cancer Presents Promising Preclinical Data on Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Nov-08-24 07:06AM	Beyond Air Inc (XAIR) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com) -6.86%
Oct-29-24 04:22PM	Beyond Air Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast (GlobeNewswire) +11.65% +8.78%
Oct-07-24 07:00AM	Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire) -5.45%
Oct-02-24 07:30AM	Beyond Air Partners with Healthcare Links to Expand Access to LungFit PH System Through Group Purchasing Organizations and Integrated Delivery Networks (GlobeNewswire) +10.57%
Sep-28-24 07:40AM	Beyond Air to sell 40.39M shares at 51c in private placement (TipRanks)
07:35AM	Beyond Air terminates loan, security agreements with Avenue Capital (TipRanks)
Sep-27-24 07:34AM	Beyond Air Provides LungFit PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed (GlobeNewswire)
07:32AM	Beyond Air Announces Termination of the Loan and Security Agreements with Avenue Capital (GlobeNewswire)
07:30AM	Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Sep-23-24 08:00AM	Beyond Air to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference (GlobeNewswire) -6.08%
Aug-06-24 04:05PM	Beyond Air® Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -17.38%
Jul-31-24 04:15PM	Beyond Air Publishes Peer-Reviewed Journal Article in Scientific Reports with Clinical Data Showing Nitric Oxide was Safe and Beneficial Adjunct Therapy for Subjects with Viral Pneumonia (GlobeNewswire) -5.16%
Jul-23-24 04:05PM	Beyond Air to Report First Fiscal Quarter 2025 Financial Results on August 6 (GlobeNewswire) +5.29%
Jul-16-24 04:05PM	Beyond Air To Participate in the BTIG Virtual Biotechnology Conference 2024 (GlobeNewswire)
Jul-10-24 09:55AM	Beyond Air (XAIR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks) +5.59%
Jun-26-24 08:01AM	Beyond Air, Inc. (NASDAQ:XAIR) Q4 2024 Earnings Call Transcript (Insider Monkey)
Jun-25-24 10:31AM	Jefferies Just Raised Its Price Target on Nvidia (NVDA) Stock (InvestorPlace) -51.54%

Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in the development of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. It operates through the Beyond Air, Beyond Cancer segments, and NeuroNos. The company was founded on April 28, 2015 and is headquartered in Garden City, NY.

CEO & DirectorMr. Robert Scott Goodman

Chief Financial OfficerMr. Daniel J. Moorhead CPA

Chief Operating OfficerMr. Michael A. Gaul

Principal Accounting Officer & ControllerMr. Denton Drewell

Senior Medical Director Global Clinical Leadership & Member of Scientific Advisory BoardDr. Andrew R. Colin M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lin Yi-Chien	10% Owner	Oct 01 '26	Buy	2.80	15,393	43,100	145,393	Oct 02 08:24 PM
Lin Yi-Chien	10% Owner	Sep 29 '26	Buy	2.69	3,000	8,070	128,000	Oct 02 08:24 PM
Lin Yi-Chien	10% Owner	Sep 30 '26	Buy	2.71	2,000	5,420	130,000	Oct 02 08:24 PM
Goodman Robert Scott	Chief Executive Officer	Jul 29 '26	Buy	5.76	34,722	199,999	34,822	Jul 31 06:55 PM
MOORHEAD DANIEL J	Chief Financial Officer	Jul 29 '26	Buy	5.76	4,340	24,998	4,340	Jul 31 06:21 PM

NVCT

Nuvectis Pharma Inc

XAIR

Beyond Air Inc

Upgrade your Finviz experience